Tesamorelin vs CJC-1295
Anonymous community accounts comparing tesamorelin and CJC-1295 — two GHRH analogues with different profiles. Real-world reports on visceral fat effects, body composition, cost, and who switches between them.
0 anonymous reports
We're collecting more reports on this topic.
Submit yourscommunity guides:
Community Q&A
- What is the difference between tesamorelin and CJC-1295?
- Both are GHRH analogues — they stimulate GH release by acting on pituitary GHRH receptors. The mechanism is similar; the specifics differ. Tesamorelin is the full 44-amino acid GHRH sequence (stabilised), with the strongest evidence base for visceral fat reduction — it has FDA approval for HIV-associated lipodystrophy and community accounts consistently describe it as the most targeted visceral fat compound in the GH category. CJC-1295 (without DAC) has a shorter half-life producing a more pulsatile GH release; with DAC the half-life extends to days, allowing less frequent dosing. Community accounts frame it this way: tesamorelin for visceral fat as a primary target; CJC-1295 (especially + ipamorelin) for broader body composition, sleep, and recovery goals.
- Tesamorelin vs CJC-1295 for fat loss — which is better?
- Community comparison accounts give tesamorelin the edge specifically for visceral fat reduction — the abdominal, deep fat that doesn't respond well to diet alone. CJC-1295 accounts describe more diffuse body composition improvement — less subcutaneous fat, more lean mass, better sleep — rather than targeted visceral reduction. The accounts that switch from CJC-1295 to tesamorelin do so when visceral fat is the specific concern and CJC-1295 results plateaued or were insufficient. Cost is the most commonly cited barrier to tesamorelin in comparison accounts — it is consistently described as more expensive, making CJC-1295 + ipamorelin the default choice unless visceral fat is the primary target.
- Can you stack tesamorelin with CJC-1295?
- Community accounts discussing stacking tesamorelin with CJC-1295 are rare — the community rationale is that both act on the same receptor (GHRH-R) and stacking two GHRH analogues is unlikely to produce additive benefits given receptor saturation. The more common pattern in community accounts that want both compounds' effects: tesamorelin for a defined cycle targeting visceral fat, then transitioning to CJC-1295 + ipamorelin for maintenance or broader goals. The general community advice in confessions: don't stack two GHRH analogues — choose one and pair with a GHRP (ipamorelin) for a synergistic GH pulse.
- Which should a new GH peptide user start with — tesamorelin or CJC-1295?
- Community accounts consistently recommend CJC-1295 + ipamorelin as the entry point for new GH peptide users — not tesamorelin. The reasoning across accounts: CJC-1295 protocols have more community evidence behind them, the cost is significantly lower, and the compound pair is available from more sources with more consistent quality. Tesamorelin's advantages — stronger evidence base for visceral fat, FDA approval — are described as relevant for users with a specific therapeutic target rather than as a starting point for general GH optimisation. Accounts from new users who started directly with tesamorelin are rare, and those that exist typically describe cost as the limiting factor rather than tolerability. The community framing: start with CJC-1295 + ipamorelin to understand how GH peptides respond in your body, then reassess whether tesamorelin's specific visceral fat profile addresses remaining goals.